<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>9(37)</volume><submitter>Wang J</submitter><pubmed_abstract>Sodium foscarnet is an antiviral drug against cytomegalovirus retinitis, and clinically it is used &lt;i>via&lt;/i> frequent intravitreal injection which causes various ocular complications. Here we propose to use benzathine foscarnet in a new salt form with much lower aqueous solubility, and as a potential long-acting intravitreally injectable solid form for foscarnet. Benzathine foscarnet (1 : 1) microcrystals were synthesized and evaluated both &lt;i>in vitro&lt;/i> and &lt;i>in vivo&lt;/i>. The aqueous solubility of benzathine foscarnet was 14.2 mM, which is in between those of the currently-used sodium foscarnet and our previously-reported calcium foscarnet salt. In a rabbit model, the injected microcrystals last for about 3 weeks in the vitreous, suggesting its solubility and dissolution profile is ap</pubmed_abstract><journal>RSC advances</journal><pagination>21318-21322</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9066022</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>&lt;i>In vitro&lt;/i> and &lt;i>in vivo&lt;/i> evaluation of benzathine foscarnet microcrystals as a potential intravitreal drug depot.</pubmed_title><pmcid>PMC9066022</pmcid><pubmed_authors>Liu J</pubmed_authors><pubmed_authors>Feng J</pubmed_authors><pubmed_authors>Huang Y</pubmed_authors><pubmed_authors>Tao Y</pubmed_authors><pubmed_authors>Wang J</pubmed_authors><pubmed_authors>Niu Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>&lt;i>In vitro&lt;/i> and &lt;i>in vivo&lt;/i> evaluation of benzathine foscarnet microcrystals as a potential intravitreal drug depot.</name><description>Sodium foscarnet is an antiviral drug against cytomegalovirus retinitis, and clinically it is used &lt;i>via&lt;/i> frequent intravitreal injection which causes various ocular complications. Here we propose to use benzathine foscarnet in a new salt form with much lower aqueous solubility, and as a potential long-acting intravitreally injectable solid form for foscarnet. Benzathine foscarnet (1 : 1) microcrystals were synthesized and evaluated both &lt;i>in vitro&lt;/i> and &lt;i>in vivo&lt;/i>. The aqueous solubility of benzathine foscarnet was 14.2 mM, which is in between those of the currently-used sodium foscarnet and our previously-reported calcium foscarnet salt. In a rabbit model, the injected microcrystals last for about 3 weeks in the vitreous, suggesting its solubility and dissolution profile is ap</description><dates><release>2019-01-01T00:00:00Z</release><publication>2019 Jul</publication><modification>2025-04-05T14:43:14.179Z</modification><creation>2024-10-15T07:35:35.59Z</creation></dates><accession>S-EPMC9066022</accession><cross_references><pubmed>35521341</pubmed><doi>10.1039/c9ra03070k</doi></cross_references></HashMap>